BSE · 543595
EP Biocomposites Limited
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹14 Cr with net profit ₹1 Cr — a 10.58% net margin, versus 8.51% the period before.
Shareholding
As of 2026-09-30
- Promoter70.08%
- Public29.92%
329 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 1.58× from low to high.
Risk flags
Derived from disclosed data
No flags raised by the data.
Peer comparison
Miscellaneous · ranked #1 of 556 by market cap · medians across 50 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| National Stock Exchange Of India Ltd. | ₹4,92,537 Cr | 44.59 | 11.77 | 26.24% | 62.66% |
| Adani Ports & Special Economic Zone Ltd. | ₹4,38,513 Cr | 31.72 | 4.29 | 13.33% | 31.98% |
| Eternal Limited | ₹3,50,935 Cr | 713.04 | 11.23 | 1.58% | 0.63% |
| BSE Limited | ₹1,60,613 Cr | 52.11 | 20.2 | 38.76% | 53.09% |
| Vedanta Aluminium Metal Limited | ₹1,48,517 Cr | 7.86 | 6.44 | 80.07% | 23.43% |
| One 97 Communications Ltd. | ₹1,24,615 Cr | 148.65 | 7.52 | 5.15% | 8.95% |
| GAIL (India) Ltd. | ₹1,23,612 Cr | 9.79 | 1.27 | 13.05% | 7.91% |
| Meesho Limited | ₹1,19,049 Cr | — | 28.31 | -21.93% | -6.19% |
| GMR Airports Limited | ₹1,05,544 Cr | 165 | 0 | -25.64% | 3.13% |
| Multi Commodity Exchange of India Ltd. | ₹94,857 Cr | 52.73 | 27.05 | 51.22% | 58.86% |
| EP Biocomposites Limited(this company) | — | — | — | — | — |
AI analysis
AI-generated · google/gemini-2.5-flashEP Biocomposites Limited is listed with a market capitalization of Rs 29 Cr. The company reported revenue of Rs 12.115 Cr in March 2025.
Positives
- +Promoter shareholding is high at 70.0812% as of March 2026.
- +Debt-to-equity ratio is low at 0.24, indicating manageable debt.
- +Revenue increased by 65.98% from Rs 7.297 Cr in March 2023 to Rs 12.115 Cr in March 2025.
- +Net profit increased by 78.92% from Rs 0.5761 Cr in March 2023 to Rs 1.0308 Cr in March 2025.
Negatives
- −No quarterly results have been disclosed since March 2026.
- −No dividend yield is disclosed in the provided data.
- −The institutional shareholding was 0% as of March 2026.
- −Foreign Institutional Investors (FII) holding decreased from 2.2004% in March 2024 to 0% in June 2024 and March 2026.
Financial performance
EP Biocomposites Limited reported revenue of Rs 12.115 Cr in March 2025. This marks a revenue increase from Rs 7.297 Cr in March 2023. Net profit for March 2025 was Rs 1.0308 Cr, following a net profit of Rs 0.5761 Cr in March 2023. The company's EBITDA for March 2025 stood at Rs 1.7716 Cr.
Profitability & returns
The company's earnings per share (EPS) was Rs 6.13 in March 2025, compared to Rs 3.94 in March 2023. EBITDA increased from Rs 1.0169 Cr in March 2023 to Rs 1.7716 Cr in March 2025. Net profit for March 2025 was Rs 1.0308 Cr.
Balance sheet
EP Biocomposites Limited has a debt-to-equity ratio of 0.24. No other balance sheet specific figures like book value are available in the provided data.
Ownership & pledges
As of March 2026, promoters held 70.0812% of the company's shares. Public shareholding was 29.9188% in the same period. There was no promoter pledge reported as of March 2026. The number of shareholders increased from 7 in February 2022 to 353 in March 2026.
Regulatory & surveillance
There is no information provided regarding any regulatory surveillance measures for EP Biocomposites Limited. No quarterly results were disclosed in the provided data.
Data as of — price: 2026-11-14 · financials: Mar 26 · shareholding: Sep 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.